GEN Exclusives

More »

GEN News Highlights

More »
Dec 20, 2007

Ablynx Extends Agreement with Wyeth for One Year

  • Ablynx extended its TNF-alpha partnership with Wyeth Pharmaceuticals for another year. The alliance is based on Ablynx’ Nanobody® technology.

    Under the terms of the original agreement, the companies will collaborate to advance novel biologics through clinical development. Wyeth has the exclusive rights to the development and commercialization of the anti-TNF-alpha Nanobodies developed under this agreement.

    Ablynx has already received an initial payment for research. Potential fees could total up to $212.5 million for development. Ablynx will also get royalties on product sales.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »